Shares of Sai Life Sciences continued their strong upward momentum on Wednesday, September 2, hitting a fresh lifetime high even as the broader Indian equity market witnessed heavy selling pressure.

CRDMO growth, strong order visibility and expansion into high-value therapies keep investors bullish on Sai Life Sciences

Shares of Sai Life Sciences continued their strong upward momentum on Wednesday, September 2, hitting a fresh lifetime high even as the broader Indian equity market witnessed heavy selling pressure.

The stock gained around 4 per cent intraday on the BSE to touch ₹1,578, extending the previous day's gains. The sharp move came at a time when the benchmark Sensex was down around 0.7 per cent, highlighting the pharmaceutical company's significant relative outperformance.

Sai Life Sciences has now gained approximately 8 per cent over the past two trading sessions. The stock has delivered an even stronger performance over a longer period, rising nearly 19 per cent in the past month and around 80 per cent over the past seven months.

In comparison, the BSE Sensex declined about 2.8 per cent over the past month, underlining the stock's ability to outperform the broader market.

Trading activity has also increased sharply. Combined volumes on the NSE and BSE were around 1.4 million shares, with average trading volume more than doubling.

Stock hits new lifetime high at ₹1,578

The latest rally pushed Sai Life Sciences into uncharted territory.

The stock touched an intraday high of ₹1,578, which is also its new 52-week and lifetime high. Its 52-week low stands at ₹783.85, indicating the substantial re-rating the stock has experienced over the past year.

The sustained upward movement suggests that investors are increasingly pricing in stronger growth from the company's contract research, development and manufacturing operations.

However, after a substantial rally, the stock is also likely to remain sensitive to quarterly earnings, order wins and management commentary.

Why Sai Life Sciences is outperforming the market

The stock's recent performance is being supported by several fundamental factors.

Sai Life Sciences operates in the contract research, development and manufacturing organisation (CRDMO) industry, an area benefiting from the increasing outsourcing of pharmaceutical research and manufacturing activities.

Global pharmaceutical and biotechnology companies are increasingly working with specialised external partners to access scientific expertise, manufacturing capacity and complex technology without having to build all capabilities internally.

This structural outsourcing trend is creating a favourable environment for established Indian CRDMO companies.

Global pharma outsourcing remains a structural opportunity

The pharmaceutical industry is undergoing a significant shift in its manufacturing and R&D strategies.

Drug developers are increasingly looking for partners that can support multiple stages of the product lifecycle, from early research and development through clinical-stage manufacturing and commercial production.

This creates an opportunity for integrated CRDMO companies.

For Sai Life Sciences, the ability to participate across multiple stages of drug development can potentially increase customer engagement and create opportunities for longer-term relationships.

India emerges as a preferred CRDMO destination

India is gaining importance in the global pharmaceutical outsourcing ecosystem due to its combination of scientific talent, manufacturing capabilities and cost competitiveness.

According to information cited by Sai Life Sciences in its FY26 annual report, India's domestic CRDMO market was estimated at approximately $3.4-$4.0 billion in CY2025.

The market is projected to grow at a 15-16 per cent CAGR between CY2026 and CY2035, potentially reaching $7-$9 billion by CY2030 and $14-$18 billion by CY2035.

Such growth could create a large opportunity for Indian companies with specialised research and manufacturing capabilities.

Complex therapies are driving demand

A major structural driver for CRDMO companies is the growing complexity of new medicines.

Pharmaceutical companies are increasingly developing advanced therapies, including:

Antibody-drug conjugates
Cell and gene therapies
Peptides
High-potency APIs
Biologics
Other specialised treatments

These therapies often require specialised facilities, sophisticated processes and stringent quality systems.

Consequently, pharmaceutical innovators may prefer to work with specialised outsourcing partners rather than developing every capability internally.

This trend can create higher-value opportunities for CRDMO companies.

Sai Life's CRO business delivers strong growth

Sai Life Sciences' contract research organisation business has been a key contributor to its recent performance.

According to Jefferies' CRDMO sector review, Sai Life's CRO business grew 24 per cent year-on-year, while margins also improved.

The performance was stronger than expected and contributed to the brokerage's constructive view on the company.

Strong CRO growth is particularly important because research services can create a pipeline for future development and manufacturing opportunities.

Strong RFP inflows signal healthy demand

Management commentary has pointed towards healthy request-for-proposal (RFP) inflows from Big Pharma customers.

RFP activity provides an early indication of potential future project opportunities.

Continued inflows from large pharmaceutical companies could support the company's order pipeline and provide greater visibility over future revenue.

The quality and conversion rate of these opportunities will therefore remain an important monitorable for investors.

More than 90% of FY27 targeted revenue already covered

One of the strongest indicators supporting the company's near-term outlook is its high order visibility.

Sai Life Sciences has indicated that more than 90 per cent of its targeted FY27 revenue is already covered by orders in hand.

Such high revenue coverage provides considerable visibility for the current financial year.

It also gives management greater confidence to plan capacity, manpower and capital expenditure.

For investors, the key issue will now be the pace at which these orders are executed and converted into reported revenue.

FY27 revenue expected to be back-ended

The company expects a larger portion of FY27 revenue to be generated during the second half of the financial year.

Sai Life Sciences expects its FY27 revenue mix to be approximately 40:60 between the first and second halves, compared with 48:52 in FY26.

This indicates that the second half is expected to contribute a significantly larger share of annual revenue.

Jefferies believes this setup could support more than 20 per cent sales growth in FY27, provided execution remains on track.

Margin expansion could support earnings growth

Revenue growth is not the only factor attracting investors.

Margin improvement is another important part of the company's investment story.

Higher utilisation, improving business mix and increasing contribution from specialised services can create operating leverage for CRDMO companies.

If Sai Life Sciences continues to improve margins while delivering double-digit revenue growth, earnings could potentially grow faster than sales.

This makes operating-margin performance an important factor to track in upcoming quarters.

Peptide business could open a new growth avenue

Sai Life Sciences is also expanding into peptides, one of the faster-growing areas of pharmaceutical development.

The company's dedicated peptide development laboratory is expected to come online shortly and will have the capability to support clinical batches.

This would allow Sai Life Sciences to build capabilities in a specialised segment where pharmaceutical and biotechnology companies increasingly require external development and manufacturing support.

Greenfield peptide facility planned for FY28

The company's peptide ambitions extend beyond development services.

Sai Life Sciences plans to break ground on a greenfield peptide manufacturing facility in FY28.

The facility could significantly strengthen its long-term capabilities in peptide manufacturing and potentially enable the company to participate in larger commercial opportunities.

The expansion also reflects the broader industry trend towards higher-value and more specialised pharmaceutical outsourcing.

CRDMO industry records strong growth

The positive outlook is not limited to Sai Life Sciences.

According to Jefferies, the broader CRDMO sector recorded around 19 per cent year-on-year growth, its strongest performance in seven quarters.

Major companies such as Divi's Laboratories, Laurus Labs, Gland Pharma, Piramal Pharma and Sai Life Sciences have benefited from improving demand conditions.

Total sales, including non-CRDMO businesses, grew around 14 per cent year-on-year.

The sector commentary remains positive for FY27, supported by strong outsourcing demand and increasing requirements for complex therapies.

Long-term partnerships can improve revenue visibility

One of the attractive features of the CRDMO business model is the potential for long-term customer relationships.

Once a pharmaceutical company establishes a successful working relationship with a CRDMO provider, the supplier can potentially remain involved as a drug progresses through different stages of development.

This can create opportunities for repeat business and improve revenue visibility.

However, maintaining such relationships requires consistent regulatory compliance, quality, delivery performance and technical capabilities.

Big Pharma exposure creates growth opportunities

Strong RFP inflows from large pharmaceutical companies can potentially improve the quality of Sai Life Sciences' order pipeline.

Large global customers typically have substantial drug-development pipelines and may require outsourcing partners for multiple projects.

Winning such programmes can therefore create opportunities beyond a single contract.

At the same time, investors need to monitor customer concentration because dependence on a limited number of large customers can increase earnings volatility if projects are delayed or cancelled.

India's pharmaceutical ecosystem provides an advantage

Sai Life Sciences operates within India's broader pharmaceutical ecosystem, which includes a large base of generic-drug manufacturers, contract manufacturers, research organisations and specialised suppliers.

This ecosystem can provide access to:

Scientific talent
Manufacturing expertise
Regulatory experience
Engineering capabilities
Pharmaceutical supply chains
Cost-efficient operations

These factors strengthen India's competitiveness in global pharmaceutical outsourcing.

Growth comes with execution requirements

The CRDMO opportunity is attractive, but growth depends heavily on execution.

Companies must be able to meet strict quality and regulatory requirements while simultaneously expanding capacity.

For Sai Life Sciences, successfully scaling new capabilities such as peptides will require capital expenditure, specialised employees and customer acquisition.

The company's ability to maintain high utilisation levels at new facilities will therefore be important for generating attractive returns on investment.

Key risks investors should monitor

Despite the positive business outlook, investors should not overlook the risks associated with the sharp stock rally.

Valuation risk

After gaining around 80 per cent in seven months, the stock has already seen a substantial re-rating. Higher valuations can leave the stock vulnerable to corrections if earnings growth falls short of expectations.

Execution risk

High order visibility does not automatically translate into revenue. Delays in project execution, regulatory approvals or customer timelines can affect growth.

Customer concentration

Dependence on large pharmaceutical customers can create volatility if major projects are delayed or contracts are not renewed.

Regulatory risk

CRDMO companies operate under stringent global quality and regulatory requirements. Any significant compliance issue could affect operations and customer relationships.

Capital expenditure risk

New peptide and other specialised facilities require substantial investments. Returns will depend on successful customer acquisition and capacity utilisation.

Biotechnology funding cycle

Some CRDMO demand is linked to biotechnology research spending. Changes in funding conditions can influence early-stage project activity.

Analyst remains constructive on Sai Life Sciences

Jefferies has maintained a Buy rating on Sai Life Sciences with a target price of ₹1,610 per share.

The brokerage's positive view is supported by the company's strong CRO growth, margin improvement, RFP momentum, high FY27 order coverage and expansion into peptides.

With the stock already trading close to the brokerage's target price after reaching ₹1,578, future upside is likely to depend increasingly on earnings delivery and further upward revisions to growth expectations.

What investors should track going forward

Investors should focus on several key indicators rather than stock-price momentum alone.

Order wins: Sustained RFP inflows and new project wins would support future growth.

Order conversion: The ability to convert the existing order pipeline into revenue will be critical.

CRO growth: Continued strong growth in research services would support the overall business.

Margins: Further operating-margin improvement could accelerate earnings growth.

Peptide development: The commissioning of the peptide laboratory will be an important milestone.

FY28 manufacturing investment: Progress on the planned greenfield peptide facility will provide clues about the company's longer-term growth strategy.

Customer diversification: A broader customer base can reduce concentration risk.

Capacity utilisation: New facilities need to achieve healthy utilisation to generate attractive returns.

Sai Life Sciences stands out in a weak market

The stock's ability to hit a fresh lifetime high while the benchmark indices were under significant pressure demonstrates strong relative momentum.

The market appears to be rewarding the company's exposure to a rapidly expanding CRDMO industry, strong order visibility and potential for continued earnings growth.

The structural opportunity is further strengthened by India's increasing role in global pharmaceutical outsourcing and the growing complexity of drug development.

Nevertheless, the sharp appreciation in the stock price means that future performance will depend increasingly on actual earnings delivery rather than simply sector optimism.

Market Outlook

Sai Life Sciences has a strong structural growth story, supported by the expansion of the global CRDMO industry, increasing pharmaceutical outsourcing and rising demand for complex therapies.

The company's 24 per cent CRO growth, more than 90 per cent FY27 revenue coverage through existing orders, healthy Big Pharma RFP inflows and planned peptide expansion provide multiple potential growth drivers.

The broader Indian CRDMO market's expected 15-16 per cent CAGR through CY2035 further strengthens the industry's long-term opportunity.

However, the stock's approximately 80 per cent rise over seven months means valuation and execution risks are becoming increasingly important. Investors should avoid judging the opportunity purely on recent price momentum and instead track revenue conversion, margins, order wins, customer diversification and returns from new capacity.

If Sai Life Sciences continues to deliver strong growth while successfully moving into higher-value areas such as peptides and advanced therapies, the company could remain well positioned to benefit from India's expanding role in the global pharmaceutical outsourcing ecosystem.